Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib

Janus kinase inhibitors (JAKis) are the most recent new drug class to arrive to the market for rheumatoid arthritis (RA) treatment. While they have proven to be a very effective treatment option, there remains significant concern regarding the risk of cardiovascular events, thrombosis and malignancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Robert, Harkins, Patricia, Conway, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607454/
https://www.ncbi.nlm.nih.gov/pubmed/37892827
http://dx.doi.org/10.3390/jcm12206690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607454/
https://www.ncbi.nlm.nih.gov/pubmed/37892827
http://dx.doi.org/10.3390/jcm12206690

Ejemplares similares